Bristol Myers Squibb’s Zenbexus, recently granted FDA accelerated approval for multiple myeloma, showed a 51% reduction in the risk of disease progression versus standard therapy in a Phase 3 trial, according to company-reported results. The update adds weight to Zenbexus’ accelerated approval package by linking it to a major progression endpoint in randomized data. Separately, Argenx said its Vyvgart failed to outperform placebo in a Phase 3 trial in Sjögren’s disease, triggering a monitoring board recommendation to stop the study for futility. The decision underscores how incremental autoimmune gains can still be difficult to translate from prior label expansions. Together, the two reads-out highlight a split regulatory picture—progression-risk reductions being emphasized on the myeloma side, while another autoimmune expansion attempt ran into late-stage efficacy headwinds.